Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthArizona Complete Health concomitant antipsychotics…
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.10

    Concomitant Antipsychotic Treatment

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.10 alerts

    Get alerted when Policy AZ.CP.PMN.10 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing prior authorization and medical necessity criteria for concomitant use of two second-generation (atypical) antipsychotics for Arizona Complete Health members (Arizona Medicaid/AzCH-CCP). Applies to prescribers and behavioral health providers managing antipsychotic therapy.

    Policy Summary
    PayerArizona Complete Health
    PolicyConcomitant Antipsychotic Treatment
    Policy CodePolicy AZ.CP.PMN.10
    Change TypeNo material change
    Effective DateJul 16, 2024
    Next Review Date
    Key ActionProviders must submit a prior authorization request for continued concomitant use beyond the 60-day POS cross-taper period.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60 daysautomatic POS approval for cross-taper
    6 monthsapproval duration
    3min trials — refractory schizophrenia
    4min trials — refractory bipolar
    BHMPprescriber requirement

    Coverage and Medical Necessity Criteria

    Initial therapy — Refractory Schizophrenia Spectrum Disorder

    Concomitant antipsychotic therapy is medically necessary when ALL of the following are met for Refractory Schizophrenia Spectrum Disorder:

    Refractory Schizophrenia Spectrum Disorder: 1. Diagnosis of Schizophrenia, Schizoaffective disorder, or Schizophreniform disorder; 2. Prescribed by a contracted Behavioral Health Medical Professional (BHMP); 3. Evidence of adequate trials of at least three (3) individual antipsychotics listed on the AHCCCS Behavioral Health Drug Lists, each for 4–6 weeks at maximum tolerated doses; 4. Treatment failure due to ONE of the following: (a) inadequate response at maximum tolerated dose; (b) adverse reaction(s); or (c) documented breakthrough symptoms; 5. Provider documentation that nonadherence to the treatment regimen did not contribute to lack of response.trials: >=3; trial duration: 4-6 weeks; approval duration: 6 months

    Approval duration = 6 months

    Initial therapy — Refractory Bipolar Disorder

    Concomitant antipsychotic therapy is medically necessary when ALL of the following are met for Refractory Bipolar Disorder with Psychosis and/or Severe Symptoms:

    Refractory Bipolar Disorder with Psychosis/Severe Symptoms: 1. Diagnosis of Bipolar disorder with Psychosis and/or Severe Symptoms; 2. Evidence of adequate trials of at least four (4) evidence‑based treatment options dependent upon episode type (may include combination therapy of antipsychotics and mood stabilizers and/or anticonvulsants), each for 4–6 weeks at maximum tolerated doses; 3. Treatment failure due to ONE of the following: (a) inadequate response at maximum tolerated dose; (b) adverse reaction(s); or (c) breakthrough symptoms; 4. Provider documentation that nonadherence to the treatment regimen did not contribute to lack of response.trials: >=4; trial duration: 4-6 weeks; approval duration: 6 months

    Approval duration = 6 months

    Initial therapy — Other diagnoses

    Other diagnoses/indications:

    Other indications: For diagnoses not specifically listed in this policy, refer to the AHCCCS FFS Prior Authorization Guideline — Coverage of Off‑Label Non‑FDA Approved Indications. Coverage for non‑listed or off‑label indications requires sufficient documentation of efficacy and safety per that guideline or applicable coverage documents.per off‑label guideline

    Continued therapy

    Continued therapy criteria (must meet ALL listed per category):

    Continued — Refractory Schizophrenia spectrum disorders: 1. Member is currently receiving the medication via the Centene benefit or has previously met initial approval criteria; 2. Documentation of positive clinical response to therapy.approval duration: 6 months
    Continued — Refractory Bipolar Disorder with Psychosis/Severe Symptoms: 1. Member is currently receiving the medication via the Centene benefit or has previously met initial approval criteria; 2. Documentation of positive clinical response to therapy.approval duration: 6 months
    Continued — Other diagnoses/indications: 1. For non‑FDA approved indications not addressed in this policy, meet one of the following: (a) sufficient documentation of efficacy and safety per the AHCCCS FFS Off‑Label Prior Authorization Guideline; OR (b) evidence of coverage in applicable coverage documents.per off‑label guideline

    Concomitant LAI + oral antipsychotic review

    When concomitant use involves a long‑acting injectable (LAI) second‑generation antipsychotic and an oral second‑generation antipsychotic:

    Apply dual-policy review: Use the AHCCCS FFS PA Criteria on Antipsychotics to review the LAI antipsychotic AND use AZ.CP.PMN.10 (Concomitant Antipsychotic Treatment) to review the oral antipsychotic. Cross‑tapers are automatically approved at point of sale for 60 days; prior authorization is required for continued concomitant use beyond 60 days.POS cross-taper: 60 days

    Follow AHCCCS FFS PA Criteria for LAI agents and AZ.CP.PMN.10 for the oral agent

    Prescriptions for concomitant antipsychotic treatment that are written by clinicians who are not Behavioral Health Medical Professionals (BHMP) are not authorized for coverage. Providers must ensure the prescriber meets the behavioral health credentialing requirement in order for coverage to be considered.

    Non‑FDA approved (off‑label) indications that are not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient documentation of efficacy and safety consistent with the AHCCCS FFS Prior Authorization Guideline — Coverage of Off‑Label Non‑FDA Approved Indications. Follow that guideline when requesting coverage for off‑label uses.

    Administrative updates to this policy removed references to the Care1st Health plan and its logos. The removal is administrative only and does not change clinical criteria or coverage requirements.

    For clarity, coverage is not authorized for non‑FDA approved indications that are not addressed in this policy unless the provider supplies the required off‑label documentation per the AHCCCS FFS Prior Authorization Guideline.

    This clinical policy is intended to serve as a guide to medical necessity to assist in coverage determinations and benefit administration. It is not a contract, a guarantee of payment, nor a substitute for professional medical judgment. Coverage decisions remain subject to the member's coverage documents, applicable state and federal requirements, and Health Plan administrative policies.

    Provider Responsibilities and Authorization Requirements

    Prior Authorization

    POS cross-tapers: 60-day automatic approval, PA required thereafter

    Cross-tapers are automatically approved at the Point of Sale (POS) for 60 days. Providers must submit a prior authorization request for continued concomitant use of any two atypical antipsychotics beyond the 60-day POS cross-taper period.

    • Automatic POS approval = 60 days
    • PA required for continued concomitant use beyond 60 days
    Prior Authorization

    Dual-policy review for LAI + oral antipsychotics

    When a long‑acting injectable (LAI) second‑generation antipsychotic is used with an oral second‑generation antipsychotic, apply the AHCCCS FFS PA Criteria to the LAI and use AZ.CP.PMN.10 (this policy) to review the oral antipsychotic.

    • Follow AHCCCS FFS PA Criteria for the LAI agent
    • Use AZ.CP.PMN.10 to review the oral antipsychotic

    Antipsychotic Medications and Formulations

    Antipsychotic medications (oral and long-acting injectable formulations)

    Antipsychotic medications included (oral and long‑acting injectable formulations):

    Formulation guidance: Concomitant use includes combinations of oral and injectable dosage forms of the same agent (e.g., aripiprazole oral + Abilify Maintena). Only preferred or formulary atypical antipsychotics listed in the policy are included; examples include aripiprazole (oral, Maintena, Aristada, MyCite), clozapine, lurasidone, olanzapine, paliperidone (Sustenna, Trinza), quetiapine, risperidone (including Consta and Perseris), ziprasidone, and other AHCCCS‑listed agents. For age limits and preferred status, refer to the AHCCCS FFS PA Criteria and the AHCCCS Behavioral Health Drug Lists.

    Antipsychotic medication (LAI and oral)

    When a long‑acting injectable (LAI) second‑generation antipsychotic is used together with an oral second‑generation antipsychotic:

    LAI and oral agents: Apply AHCCCS FFS PA Criteria to the LAI antipsychotic and AZ.CP.PMN.10 Concomitant Antipsychotic Treatment to the oral antipsychotic; cross‑tapers at point of sale are automatically approved for 60 days, with prior authorization required for ongoing concomitant use beyond 60 days.

    Clinical Background and Scope

    Concomitant use of two second‑generation antipsychotics may be considered in members with refractory psychotic disorders (for example, schizophrenia spectrum disorders) or severe bipolar disorder with psychosis or severe symptoms when multiple adequate trials of monotherapy or other evidence‑based options have failed and adherence has been confirmed. The rationale is that, after documented failure of appropriate monotherapy trials (typically a minimum of three adequate antipsychotic trials for refractory schizophrenia and four evidence‑based trials or combinations for refractory bipolar presentations), carefully selected concomitant therapy can be medically necessary to manage persistent psychosis or severe mood‑related symptoms. Long‑acting injectable plus oral combinations are cross‑referenced to AHCCCS FFS LAI criteria and reviewed together using the LAI criteria for the injectable and this policy for the oral agent.

    Terminology

    BHMP — Behavioral Health Medical Professional definition
    TermBehavioral Health Medical Professional (BHMP)
    DefinitionA contracted behavioral health professional authorized to prescribe antipsychotic medications for members.
    Policy requirementPrescribers must be contracted behavioral health professionals (BHMP) for concomitant antipsychotic approvals.
    Reference locationAppendix A: Abbreviation/Acronym Key; Policy description notes BHMP prescriber requirement.
    POS — Point of Sale automatic approval definition
    TermPoint of Sale (POS) automatic approval
    Definition

    Policy Revision History

    2025-02-10annual_reviewLatest

    Annual review: removed references to Care1st Health plan and logos; removed reference to retired policy AZ.CP.PMN.53 and added AHCCCS FFS Prior Authorization Guideline for Off‑Label Non‑FDA Approved Indications.

    2024-02-01annual_review

    1Q 2024 annual review: no significant clinical changes; references reviewed and updated.

    2023-02-09annual_review
    Policy Summary
    PayerArizona Complete Health
    PolicyConcomitant Antipsychotic Treatment
    Policy CodePolicy AZ.CP.PMN.10
    Change TypeNo material change
    Effective DateJul 16, 2024
    Next Review Date
    Key ActionProviders must submit a prior authorization request for continued concomitant use beyond the 60-day POS cross-taper period.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProvider Responsibilities and Authorization RequirementsAntipsychotic Medications and FormulationsClinical Background and ScopeTerminologyPolicy Revision History
    Step Therapy

    Required medication trials before approval

    Document adequate prior medication trials at maximum tolerated doses for the specified durations before requesting concomitant therapy: three (3) individual antipsychotic trials for refractory schizophrenia and at least four (4) evidence‑based treatment options (which may include combination therapy) for refractory bipolar disorder with psychosis/severe symptoms.

    • Refractory schizophrenia: ≥3 individual antipsychotic trials, 4–6 weeks each at maximum tolerated doses
    • Refractory bipolar with psychosis/severe symptoms: ≥4 evidence‑based treatment options (may include antipsychotic+mood stabilizer/anticonvulsant), 4–6 weeks each at maximum tolerated doses
    Note

    Policy context and clinical judgment

    (Reserved)

    Documentation Required

    Required supporting documentation to accompany PA

    Submit supporting clinical documentation with the prior authorization request to show approval criteria are met, including office chart notes, laboratory results, and evidence that nonadherence did not contribute to lack of response.

    • Office chart notes and relevant labs
    • Documentation that adherence was not a contributing factor to treatment failure
    Documentation Required

    Continued therapy: required documentation of ongoing benefit

    For continued therapy, provide documentation that the member is currently receiving the medication via the Centene benefit (or previously met initial approval criteria) and that there is a positive clinical response to therapy.

    • Evidence member is currently receiving medication via Centene benefit or previously met initial approval criteria
    • Documentation of positive response to therapy
    Documentation Required

    Professional judgment and coverage context

    Providers are expected to exercise professional medical judgment when applying these criteria. Coverage determinations remain subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable Health Plan administrative policies.

    Denial Risk

    Unauthorized prescribers are excluded

    Prescriptions written by non‑behavioral health professionals are excluded from coverage; prescribers must be contracted Behavioral Health Medical Professionals (BHMPs).

    • Coverage excluded for prescriptions by non‑behavioral health professionals
    • Prescriber requirement: contracted BHMP
    Denial Risk

    Off‑label indications: off‑label guideline documentation required

    Non‑FDA approved (off‑label) indications not addressed in this policy require sufficient documentation of efficacy and safety per the AHCCCS FFS Prior Authorization Guideline for Off‑Label Non‑FDA Approved Indications; otherwise coverage is not authorized.

    • Refer to AHCCCS FFS Prior Authorization Guideline for Off‑Label Non‑FDA Approved Indications for nonlisted diagnoses
    • Coverage not authorized without sufficient off‑label documentation
    Note

    State Medicaid provisions take precedence

    For Medicaid members, state Medicaid coverage provisions take precedence over this clinical policy when conflicts exist; providers should follow the applicable state Medicaid manual provisions.

    • State Medicaid provisions override this policy in case of conflict
    • Refer to state Medicaid manual for applicable coverage provisions
    POS cross-taper: 60 days

    From policy guidance; follow AHCCCS criteria for LAI review

    A short automatic approval period applied at the point of sale allowing cross-tapering of two antipsychotics without prior authorization.
    Duration and actionCross-tapers will automatically be approved for 60 days at the Point of Sale (POS); prior authorization is required for continued concomitant use beyond 60 days.
    Policy notePOS approvals include combinations of oral and injectable dosage forms of the same agent (e.g., Abilify + Abilify Maintena).
    Concomitant antipsychotic treatment — definition including LAI + oral combinations
    DefinitionConcomitant antipsychotic treatment = use of more than one antipsychotic medication concurrently, including combinations of a long-acting injectable (LAI) second-generation antipsychotic and an oral second-generation antipsychotic.
    ExamplesIncludes oral + oral, LAI + oral, and oral + injectable formulations of the same agent (e.g., Abilify + Abilify Maintena; risperidone + Risperdal Consta).
    Review guidance for LAI + oralWhen an LAI second-generation antipsychotic is used concomitantly with an oral second-generation antipsychotic, apply AHCCCS FFS PA Criteria to the LAI and use AZ.CP.PMN.10 to review the oral antipsychotic.
    Policy implicationConcomitant use scenarios that begin as POS cross-tapers are subject to the 60-day automatic approval; continued use requires prior authorization per policy.

    1Q 2023 annual review: added guidance for concomitant use of a long‑acting injectable (LAI) second‑generation antipsychotic and an oral second‑generation antipsychotic to apply AHCCCS FFS PA Criteria to the LAI and this policy to the oral agent.

    2021-05-10administrative_update

    Added Care1st logo and verbiage specifying criteria also applied to Care1st (later removed).